Tokio Marine Asset Management Co. Ltd. Has $1.48 Million Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Tokio Marine Asset Management Co. Ltd. raised its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 0.8% during the third quarter, Holdings Channel.com reports. The fund owned 21,105 shares of the biotechnology company’s stock after purchasing an additional 173 shares during the period. Tokio Marine Asset Management Co. Ltd.’s holdings in BioMarin Pharmaceutical were worth $1,483,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the business. AGF Management Ltd. acquired a new stake in shares of BioMarin Pharmaceutical during the second quarter worth $2,563,000. Susquehanna Fundamental Investments LLC acquired a new position in shares of BioMarin Pharmaceutical during the 2nd quarter worth about $5,627,000. Teachers Retirement System of The State of Kentucky increased its stake in shares of BioMarin Pharmaceutical by 17.4% in the 2nd quarter. Teachers Retirement System of The State of Kentucky now owns 194,207 shares of the biotechnology company’s stock valued at $15,990,000 after acquiring an additional 28,837 shares during the last quarter. E Fund Management Co. Ltd. raised its position in shares of BioMarin Pharmaceutical by 167.4% in the 2nd quarter. E Fund Management Co. Ltd. now owns 13,480 shares of the biotechnology company’s stock valued at $1,110,000 after acquiring an additional 8,438 shares during the period. Finally, Tidal Investments LLC raised its position in shares of BioMarin Pharmaceutical by 65.5% in the 1st quarter. Tidal Investments LLC now owns 17,447 shares of the biotechnology company’s stock valued at $1,524,000 after acquiring an additional 6,906 shares during the period. Institutional investors and hedge funds own 98.71% of the company’s stock.

Insider Buying and Selling at BioMarin Pharmaceutical

In other news, EVP Charles Greg Guyer sold 5,278 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $66.37, for a total transaction of $350,300.86. Following the completion of the transaction, the executive vice president now directly owns 68,909 shares in the company, valued at approximately $4,573,490.33. The trade was a 7.11 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 1.85% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Wells Fargo & Company lowered their target price on shares of BioMarin Pharmaceutical from $115.00 to $90.00 and set an “overweight” rating for the company in a research note on Tuesday, September 17th. UBS Group upped their price objective on shares of BioMarin Pharmaceutical from $104.00 to $106.00 and gave the company a “buy” rating in a research report on Wednesday, October 30th. Citigroup decreased their target price on BioMarin Pharmaceutical from $93.00 to $81.00 and set a “neutral” rating for the company in a research note on Wednesday, October 30th. Bank of America dropped their price target on BioMarin Pharmaceutical from $130.00 to $115.00 and set a “buy” rating on the stock in a research report on Tuesday, September 17th. Finally, William Blair cut BioMarin Pharmaceutical from an “outperform” rating to a “market perform” rating in a report on Wednesday, October 30th. Seven equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $94.16.

BioMarin Pharmaceutical Price Performance

Shares of NASDAQ BMRN opened at $65.60 on Friday. BioMarin Pharmaceutical Inc. has a fifty-two week low of $65.35 and a fifty-two week high of $99.56. The stock has a market capitalization of $12.50 billion, a price-to-earnings ratio of 39.28, a PEG ratio of 0.65 and a beta of 0.31. The company has a debt-to-equity ratio of 0.11, a current ratio of 4.27 and a quick ratio of 2.62. The business has a 50-day moving average of $71.24 and a 200-day moving average of $79.38.

BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its quarterly earnings data on Tuesday, October 29th. The biotechnology company reported $0.55 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.78 by ($0.23). BioMarin Pharmaceutical had a return on equity of 8.53% and a net margin of 11.71%. The company had revenue of $746.00 million for the quarter, compared to the consensus estimate of $703.37 million. During the same quarter in the prior year, the company earned $0.26 EPS. The company’s revenue for the quarter was up 28.4% on a year-over-year basis. As a group, sell-side analysts predict that BioMarin Pharmaceutical Inc. will post 2.47 earnings per share for the current fiscal year.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.